CapsoVision (NASDAQ:CV) Posts Quarterly Earnings Results

Posted by on May 14th, 2026

CapsoVision (NASDAQ:CV – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, FiscalAI reports. The company had revenue of $2.79 million for the quarter.

Here are the key takeaways from CapsoVision’s conference call:

  • CapsoVision said underlying utilization remains strong, with deeper engagement in existing accounts and continued growth in end-user consumption of CapsoCam Plus across its installed base.
  • The company expects a meaningful near-term catalyst from AI Highlights, its AI-assisted reading feature for CapsoCam Plus, with FDA clearance anticipated around mid-year and a commercial launch shortly after.
  • Management highlighted progress across the pipeline, including CapsoCam Colon Gen Two remaining on track for submission in the third quarter of 2026 and enrollment beginning in the pancreatic cancer clinical study.
  • First-quarter revenue was $2.8 million, flat year over year, while gross margin declined to 48% from 54% due mainly to tariffs affecting cost of goods sold.
  • Operating expenses rose to $8.4 million as the company increased investment in R&D and clinical trials, but CapsoVision ended the quarter with $17.9 million in cash after a $14 million private placement in March.

CapsoVision Stock Performance

Shares of CV traded up $0.30 on Thursday, hitting $7.30. 110,290 shares of the stock traded hands, compared to its average volume of 119,930. CapsoVision has a one year low of $3.43 and a one year high of $15.37. The business has a 50 day simple moving average of $6.45 and a 200 day simple moving average of $6.73. The company has a market capitalization of $363.91 million and a PE ratio of -3.33.

Analyst Ratings Changes

Separately, Benchmark reduced their price target on shares of CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating for the company in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

View Our Latest Report on CV

Institutional Investors Weigh In On CapsoVision

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its holdings in CapsoVision by 34.1% in the fourth quarter. Geode Capital Management LLC now owns 154,264 shares of the company’s stock worth $1,649,000 after purchasing an additional 39,231 shares during the last quarter. State Street Corp boosted its holdings in CapsoVision by 340.7% in the fourth quarter. State Street Corp now owns 85,929 shares of the company’s stock worth $919,000 after purchasing an additional 66,429 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in CapsoVision in the first quarter worth approximately $359,000. Citadel Advisors LLC purchased a new stake in CapsoVision in the third quarter worth approximately $115,000. Finally, Millennium Management LLC purchased a new stake in CapsoVision in the fourth quarter worth approximately $163,000.

About CapsoVision

(Get Free Report)

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.

Read More

Receive News & Ratings for CapsoVision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CapsoVision and related companies with MarketBeat.com's FREE daily email newsletter.